Why ADMET Screening Belongs at the Start of Your Pipeline

Most drug-discovery teams run ADMET profiling late. A candidate is designed for target activity, optimized for potency, tested in preliminary assays, and then — often months into the program — evaluated for absorption, distribution, metabolism, excretion, and toxicity. By that point, the team has invested significant time and budget in a scaffold that may turn out to be fundamentally flawed from a safety or pharmacokinetics perspective.

This is not because anyone thinks it is a good idea. It is because ADMET screening has historically been expensive.

The cost bottleneck

In a conventional workflow, ADMET evaluation involves either experimental assays (slow, costly, requires compound synthesis) or computational methods like DFT-derived free energy calculations (rigorous but computationally prohibitive for large candidate sets). Machine learning models offer speed, but introduce a different problem: they cannot tell you when they are guessing, they fail silently on novel scaffolds outside their training distribution, and they are not reproducible across model versions.

The result is a practical constraint: teams can only afford to run ADMET profiling on a small number of candidates, late in the pipeline, when most of the design decisions have already been made.

What happens when the cost drops to near zero?

Consider a different scenario: ADMET profiling at approximately 350 molecules per second. A full panel — solubility, permeability, CYP inhibition, hERG liability, hepatotoxicity — for 100,000 compounds in under five minutes. Deterministic results with confidence indicators. No model training, no GPU cluster, no stochastic variation between runs.

When screening becomes this fast and this cheap, the question is no longer when can we afford to run ADMET? It becomes why would we ever design a molecule without checking safety first?

This is pipeline inversion.

Pipeline inversion in practice

In an inverted pipeline, ADMET profiling moves from a late-stage gate to a first-pass filter. The workflow becomes:

The difference is structural. Instead of discovering late that your best scaffold has a CYP3A4 liability or a hERG signal, you never invest in that scaffold in the first place. Every dollar of medicinal chemistry effort goes toward candidates that have already passed a safety pre-screen.

The economics

The cost of a late-stage ADMET failure is not just the cost of the assay. It is the cost of all the design, synthesis, and optimization work invested in a candidate that should have been flagged months earlier. Industry estimates put the cost of advancing a single compound through preclinical development at $2–5 million. A significant fraction of those compounds fail for ADMET-related reasons.

If a computational pre-screen can eliminate even 10% of those late-stage failures — and the screening itself costs effectively nothing — the return on investment is difficult to overstate.

What pipeline inversion requires

Not every screening tool can support this workflow. Pipeline inversion requires four properties simultaneously:

DFT provides reproducibility and generalization but not speed. Machine learning provides speed but not generalization or confidence signals. A physics-based kernel that is both fast and deterministic — with explicit confidence indicators — is the category of tool that makes pipeline inversion practical.

The real shift

Pipeline inversion is not a feature. It is a structural change to how R&D teams allocate time and money. When the cost of asking a safety question drops to near zero, it changes when you ask it. And when you ask it first, you eliminate waste at the source rather than discovering it at the end.

The teams that adopt this workflow will not just screen faster. They will advance fewer candidates, fail earlier and cheaper, and spend their experimental budgets on molecules that have already survived a physics-based safety gauntlet.

That is the real shift.